A randomized phase II trial of fludarabine, cyclophosphamide and mitoxantrone (FCM) with or without rituximab in previously treated chronic lymphocytic leukaemia-Reference-Cited by-同舟云学术

A randomized phase II trial of fludarabine, cyclophosphamide and mitoxantrone (FCM) with or without rituximab in previously treated chronic lymphocytic leukaemia

Published:2011-01-14 Issue:5 Volume:152 Page:570-578
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:

Author:

Hillmen Peter,Cohen Dena R.,Cocks Kim,Pettitt Andrew,Sayala Hazem A.,Rawstron Andy C.,Kennedy Daniel B.,Fegan Christopher,Milligan Don W.,Radford John,Mercieca Jane,Dearden Claire,Ezekwisili Raphael,Smith Alexandra F.,Brown Julia,Booth Gillian A.,Varghese Abraham M.,Pocock Christopher,

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1365-2141.2010.08317.x/fullpdf

Reference26 articles.

1. Fludarabine, cyclophosphamide and mitoxantrone in the treatment of resistant or relapsed chronic lymphocytic leukaemia;Bosch;British Journal of Haematology,2002

2. Fludarabine, cyclophosphamide, and mitoxantrone as initial therapy of chronic lymphocytic leukemia: high response rate and disease eradication;Bosch;Clinical Cancer Research,2008

3. Rituximab, fludarabine, cyclophosphamide, and mitoxantrone: a new, highly active chemoimmunotherapy regimen for chronic lymphocytic leukemia;Bosch;Journal of Clinical Oncology,2009

4. Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial;Catovsky;The Lancet,2007

5. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment;Cheson;Blood,1996

Cited by 38 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeted therapies in CLL/SLL and the cumulative incidence of infection: A systematic review and meta-analysis;Frontiers in Pharmacology;2022-09-14

2. COSMIC, chemotherapy plus ofatumumab at standard or mega‐dose in chronic lymphocytic leukaemia, a phase II randomised study;British Journal of Haematology;2021-05-24

3. Minimal Residual Disease in Chronic Lymphocytic Leukemia: A New Goal?;Frontiers in Oncology;2019-08-29

4. Remission maintenance treatment options in chronic lymphocytic leukemia;Cancer Treatment Reviews;2018-11

5. An Evidence-based Review of Anti-CD20 Antibody-containing Regimens for the Treatment of Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Diffuse Large B-cell Lymphoma, or Follicular Lymphoma;Clinical Lymphoma Myeloma and Leukemia;2018-08